search
Back to results

Fetoscopic Endoluminal Tracheal Occlusion (FETO) With Smart-TO (Smart-FETO)

Primary Purpose

Congenital Diaphragmatic Hernia

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
FETO with Smart-TO balloon
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Congenital Diaphragmatic Hernia focused on measuring Congenital diaphragmatic hernia, Fetal endoscopic tracheal occlusion, Smart-TO balloon, Proof of concept, Safety study

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients aged 18 years or more, who are able to consent, and affiliated to social security
  • Singleton pregnancy with fetus with isolated left-sided congenital diaphragmatic hernia (no additional malformation nor chromosomal abnormality) and:

Severe pulmonary hypoplasia defined as observed on expected 'lung-to-head ration' (O/E LHR) <25% irrespective of the liver position as measured between 27wks and 29wks + 6 days Or Moderate pulmonary hypoplasia defined as O/E LHR 25-34.9% (liver up or down) or O/E LHR 35-44.9% with liver up as measured between 30wks and 31wks + 6 days

Exclusion Criteria:

  • Maternal contraindication to fetoscopic surgery
  • Preterm premature rupture of the membranes (PPROM) or condition strongly predisposing to PPROM or premature delivery
  • Impossibility of remain close to the FETO center during the fetal occlusion period

Sites / Locations

  • Hôpital BéclèreRecruiting
  • Hôpital Bicêtre

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Intervention

Arm Description

Outcomes

Primary Outcome Measures

Deflation of the Smart-TO balloon after exposure to the fringe field of the MRI
No visualization of the balloon at ultrasound scan
Expelling of the Smart-TO balloon outside the airways
Thorax X-ray of the neonate

Secondary Outcome Measures

Serious unexpected or adverse reactions
Adverse reactions monitoring during the whole study duration
Spontaneous deflation of the balloon
Ultrasound scan
Prematurity
Gestational age at birth
Preterm premature rupture of the membranes (PPROM)
Event of PPROM and gestational age at PPROM
Fetal lung growth
O/E LHR measurement
Survival at discharge
Neonate survival
Survival at 6 months of age
Neonate survival
Oxygen dependence

Full Information

First Posted
February 6, 2021
Last Updated
April 14, 2023
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT04931212
Brief Title
Fetoscopic Endoluminal Tracheal Occlusion (FETO) With Smart-TO
Acronym
Smart-FETO
Official Title
Fetoscopic Endoluminal Tracheal Occlusion (FETO) With Smart-TO Device in Fetuses With Congenital Diaphragmatic Hernia and Moderate to Severe Pulmonary Hypoplasia: Proof of Concept and Safety Evaluation.
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 4, 2021 (Actual)
Primary Completion Date
April 2024 (Anticipated)
Study Completion Date
October 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to make the proof of concept and to evaluate the safety of fetoscopic endoluminal tracheal occlusion (FETO) using Smart-TO device in fetuses with congenital diaphragmatic hernia and moderate to severe pulmonary hypoplasia
Detailed Description
Congenital diaphragmatic hernia (CDH) leads to lung hypoplasia and impaired lung vasculature. Fetal lung growth may be stimulated by fetal endoscopic tracheal occlusion (FETO). In severe CDH, FETO may improve survival. In the moderate cases, the prematurity induced by the plug-unplug strategy limits the benefit from the lung growth induced by tracheal occlusion. One of the main drawbacks of FETO is the need for in-utero reversal of tracheal occlusion by the balloon, as the current procedure involves re-establishment of patent airways either electively at 34 weeks' gestation or earlier if required, ideally at least 24 h before birth. Unfortunately, removal of the balloon is a difficult, invasive, and risky procedure. Furthermore, it requires a specialist team to be able to reverse the occlusion at all times. As a result, it is recommended that the patient stays close to a FETO center during the whole duration of the occlusion, which may limit the acceptability of FETO. The Smart-TO balloon allows an easy, remotely controlled, and non-invasive reversal occlusion, so it allows to overcome issues related to the airway reestablishment. The technology solution is based on a magnetic valve that opens under the influence of the peripheral magnetic field around a magnetic resonance (MR) scanner. The opening of the valve induces the deflation of the balloon, which is then washed out by the fluid coming out from the lungs. The purpose of this study is to make the proof of concept and to evaluate the safety of fetoscopic endoluminal tracheal occlusion (FETO) using Smart-TO device in fetuses with congenital diaphragmatic hernia and moderate to severe pulmonary hypoplasia. Secondary objectives include evaluation of prematurity, preterm premature rupture of membranes, lung growth, and survival at discharge in case of FETO with Smart-TO balloon. FETO with Smart-TO balloon will be performed between 27 and 31wks + 6 days depending on the severity of pulmonary hypoplasia, according to the same technique that is used with the balloon usually used for FETO procedure. The unplug procedure will be performed between 34 and 34wks + 6 days or earlier if required. The patient will be asked to make a peripheral course around the MR scanner in order to open the magnetic valve and induce the deflation of the balloon. Ultrasound scan will be performed before and after the unplug procedure, in order to check the balloon did not deflate spontaneously at the time of the unplug, and to check the balloon deflates thanks to the magnetic fringe field of the MR scan. Expelling of the Smart-TO balloon outside the airways will be check at birth by a thorax X-ray. Patients will be monitored during the whole duration of the study so serious unexpected or adverse reactions can be recorded.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Congenital Diaphragmatic Hernia
Keywords
Congenital diaphragmatic hernia, Fetal endoscopic tracheal occlusion, Smart-TO balloon, Proof of concept, Safety study

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Intervention Type
Procedure
Intervention Name(s)
FETO with Smart-TO balloon
Other Intervention Name(s)
Unplug
Intervention Description
Fetal endoscopic tracheal occlusion using the Smart-TO balloon Unplug procedure by peripheral course around the MR scanner
Primary Outcome Measure Information:
Title
Deflation of the Smart-TO balloon after exposure to the fringe field of the MRI
Description
No visualization of the balloon at ultrasound scan
Time Frame
Between 34 and 34+6 amenorrhea weeks
Title
Expelling of the Smart-TO balloon outside the airways
Description
Thorax X-ray of the neonate
Time Frame
At birth
Secondary Outcome Measure Information:
Title
Serious unexpected or adverse reactions
Description
Adverse reactions monitoring during the whole study duration
Time Frame
From date of inclusion until discharge date from hospitalization of newborn, up 15 months
Title
Spontaneous deflation of the balloon
Description
Ultrasound scan
Time Frame
Between the FETO (27amenorrhea weeks) and the unplug procedure (34 amenorrhea weeks)
Title
Prematurity
Description
Gestational age at birth
Time Frame
At birth
Title
Preterm premature rupture of the membranes (PPROM)
Description
Event of PPROM and gestational age at PPROM
Time Frame
from date of inclusion until delivery, up to 37 amenorrhea weeks
Title
Fetal lung growth
Description
O/E LHR measurement
Time Frame
Before the unplug procedure
Title
Survival at discharge
Description
Neonate survival
Time Frame
From date of inclusion until discharge date from hospitalization of newborn, up to 6 months
Title
Survival at 6 months of age
Description
Neonate survival
Time Frame
6 months after birth
Title
Oxygen dependence
Time Frame
6 months after birth

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients aged 18 years or more, who are able to consent, and affiliated to social security Singleton pregnancy with fetus with isolated left-sided congenital diaphragmatic hernia (no additional malformation nor chromosomal abnormality) and: Severe pulmonary hypoplasia defined as observed on expected 'lung-to-head ration' (O/E LHR) <25% irrespective of the liver position as measured between 27wks and 29wks + 6 days Or Moderate pulmonary hypoplasia defined as O/E LHR 25-34.9% (liver up or down) or O/E LHR 35-44.9% with liver up as measured between 30wks and 31wks + 6 days Exclusion Criteria: Maternal contraindication to fetoscopic surgery Preterm premature rupture of the membranes (PPROM) or condition strongly predisposing to PPROM or premature delivery Impossibility of remain close to the FETO center during the fetal occlusion period
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alexandra BENACHI, MD, PhD
Phone
01 45 37 44 76
Email
alexandra.benachi@aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Adèle BELLINO
Phone
01.58.41.11.95
Email
adele.bellino@aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anne-Gael CORDIER, MD, PhD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Nicolas SANANES, MD, PhD
Organizational Affiliation
University Hospital, Strasbourg, France
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Alexandra BENACHI, MD, PhD
Organizational Affiliation
AH-HP
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpital Béclère
City
Clamart
ZIP/Postal Code
92140
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexandra BENACHI, MD, PhD
Phone
+33 1 45 37 44 76
Email
alexandra.benachi@aphp.fr
Facility Name
Hôpital Bicêtre
City
Le Kremlin-Bicêtre
ZIP/Postal Code
94270
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Grégoire DUMERY, MD, PhD
Email
gregoire.dumery@aphp.fr

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Fetoscopic Endoluminal Tracheal Occlusion (FETO) With Smart-TO

We'll reach out to this number within 24 hrs